Introduction
Human immunodeficiency virus type 1 (HIV-1)-specific CD8 + T cells play a critical role in the control of HIV-1 infections (26, 5) , but HIV-1 escape occurs during acute and chronic phases of an HIV-1 infection (6, 14) . There are several mechanisms affording HIV-1 escape from the host immune system. They include the appearance of mutants that escape from HIV-1-specific cytotoxic T lymphocytes (CTLs) (6, 14) and neutralizing antibody (27, 47, 48) , impaired recognition of HIV-1-infected cells by HIV-1-specific CTLs due to Nef-mediated down-regulation of HLA class I molecules (8, 42) , and impaired function of HIV-1-specific T cells (3) .
It is well known that long-term non-progressors (LTNPs), who remain disease-free and have a very low or undetectable level of viral load in the absence of antiretroviral therapy, exist as a very small population of HIV-1-infected individuals (7, 21, 38) . A small minority of these LTNPs were infected by HIV-1 containing deletions in viral accessory molecules (10, 17, 24) . HLA alleles such as HLA-B*57/5801, HLA-B*27, and HLA-B*51 are associated with slow progression to AIDS (19, 22, 37) . Indeed, it is reported that many LTNPs carry these HLA alleles (31, 36) . These findings imply that HIV-1-specific CTLs restricted by these alleles may play an important role in the control of HIV-1 replication in LTNPs. The mechanism of control of HIV-1 replication has been analyzed in LTNPs and slow progressors carrying HLA-B*57/5801, HLA-B*27 or HLA-B*13, and has been related to the Gag-specific CD8 + T cell epitopes presented by these alleles (9, 11, 14, 16, 34) . On the other hand, the mechanism underlying the association between HLA-B*5101 and slow progression remains unclear. There has been no previous study reported concerning the mechanism of control of HIV-1 in HLA-B*5101 + LTNPs.
Since data indicate that HIV-1 replication can be controlled for more than 20 years in LTNP hemophiliacs, analysis of HIV-1-specific immune responses and HIV-1 in these patients is useful to investigate the immunological control of HIV-1. In Japan,
HLA-B*57/58 and HLA-B*27 are very rare alleles (18) . Therefore it was speculated that only HLA-B*51 would play an important role in the control of HIV-1 replication in HIV-1-infected Japanese donors.
We previously showed that 2 Pol peptides and 1 Gag peptide were HLA-B*5101-restricted immunodominant CTL epitopes (45) . Two Pol-specific CTLs are known to have strong ability to suppress HIV-1 replication in vitro (43) . Our recent study using 9 cohorts showed that Pol283-specific CTLs out of these T cells select mutations at position 8 (position 135 of RT) in the epitope (20) . A Thr mutation at position 8 (8T) was predominantly found in HIV-1-infected HLA-B*5101 + donors, whereas the 8R, 8L, and 8V mutations were also found in them. The 8T, 8L, and 8R mutants had similar fitness as the wild-type virus, whereas the 8V one had higher fitness cost than the other mutations.
In the present study, we analyzed the effect of HLA-B*5101 on the clinical outcome in HIV-1-infected Japanese hemophiliacs. In addition, we investigated the role of HLA-B*5101-restricted HIV-1-specific CTLs in vivo in HLA-B*5101 + LTNP and slow-progressing Japanese hemophiliacs who had not been treated with anti-retrovirus therapy for approximately 25 years. Our results revealed a role for Pol283-8-specific
HLA-B*5101-restricted HIV-1-specific CTLs in the long-lasting (approx.25 years) control of HIV-1 replication.
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Materials and methods
Patients
One hundred and eight Japanese hemophiliacs who had been infected with HIV-1 before 1985, mostly around 1983, were recruited for the present study, which was approved by the ethic committees of Kumamoto University and International Medical Center of Japan. Written informed consent was obtained from all subjects according to the Declaration of Helsinki. Patient HLA type was determined by standard sequence-based genotyping.
For sequence analysis, blood specimens were collected in EDTA. Plasma and peripheral blood mononuclear cells (PBMCs) were separated from heparinized whole blood.
Cells
C1R and .221 cells expressing HLA-B*5101 (C1R-B*5101 and .221-B5101, respectively) were previously generated (15, 33, 44) . All cells were maintained in RPMI 1640 medium supplemented with 10% FCS and 0.15 mg/ml hygromycin B.
HIV-1 clones
An infectious proviral clone of HIV-1, pNL-432 and its mutant, pNL-M20A
(containing a substitution of Ala for Met at residue 20 of Nef), were reported previously (1). viruses were generated based on pNL-432 by using the GeneTailor Site-directed Mutagenesis System (Invitrogen).
Pol283
HLA-class I tetramers
HLA-class I-peptide tetrameric complexes (tetramer) were synthesized as described 6 previously (2). Four HIV-1specific epitopes and Rev71-11) (45) were used for the refolding of HLA-B*5101 molecules. PE-labeled streptavidin (Molecular Probes) was used for generation of the tetramers.
Flow cytometric analysis using tetramers
PBMCs were incubated with the tetramers at 37 °C for 30 min. The cells were subsequently washed twice with RPMI/10% NCS and then stained with anti-CD8 mAb.
Next they were incubated at 4°C for 30 min and then were washed twice with RPMI/10%
NCS. The cells were finally resuspended in PBS containing 2% paraformaldehyde, and then the percentage of tetramer + cells among the CD8 + population was determined by using a FACSCalibur (BD Bioscience, San Jose, California, USA).
Generation of CTL clones
Pol283-8-specific CTL clones and Pol743-9-specific CTL clones were generated from the HIV-1-specific bulk-cultured T cells by limiting dilution in U-bottomed 96-well microtiter plates (Nunc, Roskilde, Denmark) containing 200 µl of cloning mixture (about 1×10 6 irradiated allogeneic PBMCs from healthy donors and 1×10 5 irradiated C1R-B*5101 cells prepulsed with the corresponding peptide at 1 µM in RPMI 1640 supplemented with 10% human plasma and 200 U/ml human rIL-2) (43).
CTL assay for target cells infected with HIV-1
The cytotoxicity of CTL clones for the .221-CD4-B5101 cells infected with HIV-1(>30% p24 Ag-positive cells) was determined by the standard 51 Cr release assay as described previously (42) . an E:T ratio of 2 : 1. The cells were then incubated for 6 hours at 37°C. The supernatants were collected and analyzed with a gamma counter.
Assay for suppression of HIV-1 replication by HIV-1-specific CTLs
The ability of HIV-1-specific CTLs to suppress HIV-1 replication was examined as previously described (42 
Cell-surface staining and intracellular cytokine staining (ICC assay)
PBMCs from HIV-1-infected individuals were stimulated with the desired peptide (1µM) and cultured for 12-14 days. These cultured PBMCs were assessed for IFN-γ-producing activity as previously described (42) . After C1R-B*5101 cells had been incubated for 60 min with epitope peptides (1 µM), they were washed twice with RPMI-1640 containing 10% FCS. These C1R cells and the cultured PBMCs were incubated at 37 °C for 6 h at an effector-to-stimulator ratio of 2 or 4:1 after the addition of Brefeldin A (10 µg/ml). Next, the cells were stained with anti-CD8 mAb (DAKO Corporation, Flostrup, Denmark), fixed with 4% paraformaldehyde at 4 °C for 20 min, and then permeabilized at 4°C for 10 min with PBS supplemented with 0.1% saponin containing 20% NCS (permeabilizing buffer).
The cells were resuspended in the permeabilizing buffer and then stained with anti-IFN-γ mAb (BD Bioscience Pharmingen, San Diego, CA). Finally they were finally resuspended in PBS containing 2% paraformaldehyde, and then the percentage of CD8 + cells positive for intracellular IFN-γ were determined by using the FACSCalibur. Table 1 ). These results together show that the HLA-B*5101 allele was still associated with slow progression of the disease more than 20 years post-infection.
Results
Association
Control of HIV-1 replication by HLA-B*5101-restricted CD8 + T cells
A previous study demonstrated that 2 HLA-B*5101-restricted CTLs, Pol283-8(TAFTIPSI)-specific and Pol743-9(LPPVVAKEI)-specific CTLs, much more strongly suppressed HIV-1 replication in vitro than did other HLA-B*5101-restricted CTLs (43) , suggesting that these CTLs may play a key role in the control of HIV-1 in the HLA-B*5101 + SP group. To investigate the control of HIV-1 by these CTLs, we selected 10 HLA-B*5101-positive donors (8 VSPs and 2 SPs) who had not been treated with ART by 1998 and whose PBMC samples were available for analysis of HLA-B*5101-restricted CTLs (suppl. Fig. 1 and suppl. Table 2 ). Three of the 8 VSP patients had a VL of less than 1,000 at all time points tested and were classified as LTNP. We found that only 3 (KI-021, KI-051, and KI-124) of the 108 HIV-1-infected hemophiliacs were LTNPs for approximately 25 years and that all 3 of these LTNPs carried HLA-B*5101. We generated 4 HLA-B*5101-tetramers carrying Pol283-8, Pol743-9, Gag327-9 or Rev71-11, and used them to determine the frequency of HIV-1-specific CD8 + T cells among PBMC from these 3 LTNPs (Table 1 and Fig. 2 ). KI-021 had both Pol283-8-and
Pol743-9-specific CD8 + T cells but neither Gag327-9-nor Rev71-11-specific CD8 + T cells during 1997-2005 ( Fig. 2A) . KI-051 also had both Pol283-8-and Pol743-9-specific CD8 + T cells, whereas this patient had no Rev71-11-specific CD8 + T cells and a low number of Gag327-9-specific CD8 + T cells during 1999-2005 (Fig.2B ). KI-124 had Pol283-8-, Pol743-9-and Gag327-9-specific CD8 + T cells (Table 1) . These results suggest that the 2
Pol-specific CD8 + T cells may play an important role in the control of HIV-1 in these LTNPs carrying HLA-B*5101.
Selection of escape mutations of Pol283-8 epitope in very slow progressors
Of the 8 HLA-B*5101 + VSP hemophiliacs, KI-127 had Pol283-8-specific CD8 + T cells at a low frequency level in 1998 when the plasma viral load (pVL) was very low; whereas later this patient lost the response with the pVL increasing from an undetectable level to more than 10 3 copies (Fig. 2C) . The other 4 VSPs had a low number of Pol283-8-specific CD8 + T cells or did not have any of these cells at any time points studied.
These results suggest that Pol283-8-specific CD8 + T cells rather than Pol743-9-specific CD8 + T cells may control HIV-1 in vivo.
To clarify the role of these HLA-B*5101-restricted CD8 + T cells in the control of HIV-1 in vivo, we analyzed the correlation between the frequency of the HLA-B*5101-restricted CD8 + T cells and pVL in 10 HLA-B*5101 + hemophiliacs. The frequency of Pol283-8-specific CD8 + T cells was negatively correlated with pVL (P=5.6X10 -8 ) , whereas that of the other T cells was positively correlated with it ( Fig.3 ).
These results support the idea that Pol283-8-specific CD8 + T cells drive the suppression of
HIV-1 replication in vivo.
We speculated, therefore, that escape mutants within Pol283-8 epitopes were selected in slow progressors over a 25-year period, because these epitope-specific CTLs are thought to provide strong immune pressure on HIV-1. Two of the LTNPs had the Pol283-8V mutant, whereas the third had the Pol283 wild type in July 2002 but the 8V mutant in October 2006 ( Table 2) . As previously noted (34), Pol283-8-specific CTL clones showed the same killing activity toward target cells prepulsed with Pol283-8V peptide as that toward those with the wild-type peptide. These T cells revealed similar killing activity toward .221-B*5101 cells infected with NL-432 carrying Pol283-8V (NL-Pol283-8V) as that toward those infected with NL-432 (suppl. Fig.2A ), and only marginally weaker ability to suppress the replication of NL-Pol283-8V (suppl. Fig.2B ). In contrast, the 5 VSPs and 2 SPs had Pol283-8T or Pol283-8R mutants (Table 2) . Three Pol283-8-specific CTL clones failed to kill target cells infected with NL-432 carrying these mutants (NL-Pol283-8T and NL-Pol283-8R, suppl. Fig.2A ) and to suppress the replication of these mutants (suppl. Fig.   2B ), indicating that these were escape mutants.
Longitudinal analysis of KI-127 showed that the the 8T mutant appeared in August 2000, when the VL had increased approximately 10-fold, whereas wild type Pol283 was found in February 1997 when the VL was very low or undetectable (Fig.2C ). Previous population analysis using 9 cohorts showed strong association between HLA-B*51 and Pol283-8T (20) . These observations together suggest that the 8T mutant is an escape mutant selected by Pol283-specific CTLs, and implies that escape from this epitope reduces immune control of HIV-1.
In vitro selection of Pol283 escape mutants by Pol283-specific CTLs
The results shown in Fig. 4 suggested that Pol283-specific CTLs selected 8T, 8R, and 8L escape mutants. To further confirm the selection of these mutants by Pol283-specific CTLs, we investigated whether Pol283-specific CTLs selected these mutant virus in vitro when the CTLs were cultured with HLA-B*5101-positive CD4 + T cells infected together with NL-432 and the mutant virus. Pol283-specific CTL clones selected these 3 mutant viruses, 8T, 8R, and 8L, rapidly in this assay (Fig. 4A-4C ), supporting the notion that these mutants were selected as escape mutants by Pol283-specific CTLs. (Fig. 5 ), indicating that these 2 patients could maintain Pol283-8-specific memory CD8 + T cells for more than 20 years. In contrast, Pol283-8T-specific CD8 + T cells were not detected among PBMC from any of these 4 donors after 2 weeks in culture (Fig. 5) ,
indicating that the Pol283-8T escape mutant did not elicit specific CD8 + T cells in vivo.
These results support the idea that the Pol283-8T mutant was selected by Pol283-8-specific
CTLs in donors first infected with the wild-type virus. Similarly, Pol283-8R-specific CD8 + T cells were not detected in KI-007; although this patient had Pol283-8-specific memory CD8 + T cells (Fig. 5) , supporting the notion that the 8R mutant was an escape mutant selected by Pol283-8-specific CTLs and failed to elicit these escape mutant-specific CTLs.
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Discussion
It is well known that HLA-B*57 and -B*27 are associated with slow progression to AIDS (19, 37) . HLA-B*57-mediated and HLA-B*27-mediated effects on disease progression are seen early and late, respectively, during an infection (6, 14) . In the present study we analyzed 108 HIV-1-infected Japanese hemophiliacs. In Japan, 1439
patients had been infected with HIV-1 before 1985, mostly around 1983. At present, only 801 of these patients remain alive. Since they had not been treated with HART before 1997, the survivors would seem to be slow progressors. This cohort does not include a large number of patients, because it is not easy to recruit a large number of HIV-1-infected hemophiliacs in Japan where only 800 of them are still alive. We found that HLA-B*5101 had effects on the slow progression of the disease in the late phase (both at 1998 as well as during 1998-2007), even when a small number of samples was analyzed.
Our recent study also revealed that HLA-B*5101 + hemophiliacs had a lower VL and higher CD4 counts than HLA-B*5101-negatives but that only the CD4 count was significantly higher in HLA-B*5101 + hemophiliacs than in HLA-B*5101-negatives (20) . These findings support the idea that HLA-B*5101-restricted immune responses are associated with slow progression to AIDS.
Pol283-8, Pol743-9, and Gag327-9 are thought to be immunodominant HIV-1 epitopes, because CTLs specific for them were frequently detected in chronically HIV-1-infected HLA-B*5101 + individuals (45) . A previous study demonstrated that Pol283-8-specific and Pol743-9-specific CTLs strongly suppress HIV-1 replication but that Gag327-9-specific ones only weakly suppress it in vitro (43) , suggesting that HIV-1 replication can be suppressed in vivo by Pol283-8-specific and Pol743-9-specific CTLs.
In the present study we demonstrated that a higher number of Pol283-8-specific CD8 + T 15 cells was predominantly detected in only LTNPs, whereas Pol743-9-specific CD8 + T cells were found at a higher level in all of the 10 of the SP hemophiliac patients examined.
ART-treated HLA-B*5101 + patients also carried Pol743-9-specific CD8 + T cells but not Pol283-8-specific ones (data not shown). The frequency of Pol283-specific CD8 + T cells was negatively correlated with pVL, whereas that of the other 3 T cells was positively correlated with it (Fig. 3) . The longitudinal analysis of KI-127 showed that the VL increased after the 8T mutant appeared. This suggests that Pol283-specific CTLs may control HIV-1 in this patient, but the possibility that other CTLs also control it cannot be excluded. These results support the notion that Pol283-8-specific CTLs play a key role in the control HIV-1 in chronically HIV-1-infected HLA-B*5101 + hemophiliacs.
Previous studies showed that Gag-specific responses are negatively correlated with VL in chronically HIV-1-infected individuals (23, 25, 28, 49) . Especially HLA-B*57/5801, HLA-B*27, HLA-B*13, or HLA-B*63-restricted Gag-specific CD8 + T cell responses are related to a low viral load (12, 16, 23, 34, 49) . However, these studies had been performed in Caucasian and African cohorts. Since HLA-B*57/5801, HLA-B*27 or HLA-B*13 are very rare in Japan, Gag-specific CD8 + T cell responses might not be related to a low pVL in Japanese patients. In HLA-B*5101 + hemophiliacs studied here, it is striking that Pol283-specific CD8 + T cell responses were much more effective in the control of HIV replication than Gag327-specific CD8 + T cell responses. A previous study revealed that SIV-infected cells are recognized earlier by Pol-specific T cells than by Nef-specific T cells (39). These results suggest that Pol-specific responses may be important in the control of HIV-1, not only in the Japanese population. This is potentially an important result in relation to vaccine design and the specificity of the CD8 + T-cell responses that are needed to be induced to achieve immune control of HIV.
Our recent study using 9 cohorts showed that there are 4 mutations (8T, 8R, 8L, and 8V) at position 8 of the Pol283 epitope and that the frequency of the 8T variant is significantly higher in HLA-B*5101 + donors than in HLA-B*5101 -ones and that some HLA-B*5101 + acute infection subjects w ho had been infected with the wild-type virus had the 8T virus at only 6 or 12 months after the first test (20) , indicating that 8T is selected by Pol283-specific CTLs. In the present study we revealed that the Pol283-8T escape mutation was detected for the first time approximately 20 years post HIV-1 infection in KI-127, indicating that this mutation had been slowly selected by Pol283-8-specific CTLs in this donor. Pol283-8R and Pol283-8L were also apparently escape mutations, because
Pol283-8-specific CTLs failed to suppress replication of HIV-1 carrying these mutants.
However, the frequency of these mutations is not significantly higher in HLA-B*5101 + donors than in HLA-B*5101-negatives (20) , suggesting that other non-HLA-B*5101-restricted CTLs may also select these particular mutants. Nonetheless, it is clear that the HLA-B*5101-restricted Pol283-specific CTLs select the 8R mutant, because KI-007, having the 8R mutant virus, possessed Pol283-specific memory T cells (Fig. 5) , and one HLA-B*5101 + subject with an acute HIV infection who had been infected with the wild-type virus had the 8R mutant 12 months after the first test (20) .
The Pol283-8V mutant was found in only 6 of 60 HLA-B*5101 + donors including 3 LTNP hemophiliacs (data not shown). Of the 3 non-hemophiliacs, two are progressors and 1 was a slow progressor. Since this mutation is rare and it is speculated that the mutations were not accumulated 25 years ago, it is unlikely that the 2 LTNP hemophiliacs had been infected with this mutant virus. On the other hand, the 3 non-hemophiliacs may have been infected with the 8V mutant. The 8V mutation did not influence the killing activity of Pol283-8-specific CTLs toward target cells infected with the HIV-1 mutant, whereas the ability of CTLs to suppress the replication of the Pol283-8V mutant was significantly weaker than that to suppress that of the wild-type virus. Previous studies showed that HIV-1-specific CTL clones can partially suppress HIV-1 replication but fail to kill HIV-1-infected CD4 + T cells (42, 45) , indicating that the replication suppression assay is a more sensitive one than the CTL assay. Since Pol283-8-specific CTLs cannot completely suppress the replication of the 8V mutant virus and the 8V virus has higher fitness cost, the donors selecting this mutant virus can be LTNP hemophiliacs. However it still remains unclear why the 8V virus appears in both LTNP and progressors. We are now analyzing the HLA-B*5101 + non-hemophiliacs carrying the 8V mutants to compare them with the LTNP carrying the 8V mutant.
Our previous study on the crystal structure of the HLA-B*5101-Pol283-8 peptide complex showed that the C-terminal anchor (PC) pocket is hydrophobic and relatively small compared with that of the serologically close alleles, HLA-B*3501 and -B*5301, whose C-terminal preferential amino acids include aromatic amino acids (30) . Those findings explain why the PC residues for HLA-B*5101 are preferably aliphatic amino acids and not bulky aromatic amino acids. The PC residue is tethered with well-ordered polar and hydrophobic interactions, as observed in other MHC class I molecules (Fig. 6A) . Thus the amino acid substitutions of the PC residue did not likely lead to large rearrangements of this network, and so the orientations of the side chains are presumably maintained. In the case of the 8R mutation, the PC pocket is not large enough to accommodate the Arg residue (Fig. 6B) , conferring structural changes around the PC pocket to possibly result in a lack of binding activity toward HLA-B*5101 (2) . The 8L mutant exhibited slightly reduced binding activity toward HLA-B*5101 and CTL recognition for 8L peptide-pulsed target cells but no CTL response toward the 8L mutant-infected cells, suggesting that the mutation had a deleterious effect on antigen presentation in the system for export to the cell surface.
The 8V mutation would delete only one methylene group from the Ile residue and thus presumably have only a small influence on the binding to HLA-B*5101 as well as on its specific TCR recognition. On the other hand, the Pol283-8T mutation likely introduces a hydrophilic OH group not likely appropriate for the hydrophobic pocket, resulting in diminished binding activity (43) . Furthermore, the Pol283-8T mutation was detrimental to the CTL response and thus may also have induced a structural rearrangement having a negative effect on the TCR recognition.
A higher accumulation of Pol283-8 escape mutations is found in the Japanese population than in other populations, because the frequency HLA-B*51 is much higher in Japan than in other countries (20) . The fitness of the 8T, 8R, 8L viruses is similar to that of the wild-type one and these escape mutants do not revert to wild-type viruses in HLA-B*5101 -donors (20) . The donors having the escape mutant viruses failed to elicit escape mutant-specific CTLs. These findings suggest a difficulty to control the replication of these mutant viruses in HLA-B*5101 + individuals initially infected with the mutant virus. We showed earlier that recently infected HLA-B*5101 + donors have no advantage for the control of HIV-1 (20) . Thus, the association between HLA-B*5101 and slow progression to AIDS may disappear in newly HIV-1-infected Japanese donors.
HLA-B*57-mediated immune pressure early selects an escape mutant of the TW10 epitope, which carries a low viral fitness (29, 32) . Escape mutations (K, G, Q, and T at position 242) of the KK10 epitope selected by HLA-B*27-mediated immune pressure impair viral replication but the compensatory mutation of S173A restores viral replication (40, 41) . Pol283-8 escape mutations (T, L, and R) are different from these escape mutations, because these Pol283-8 mutations do not influence viral fitness (43) .
HLA-B*5701 is highly associated with LTNPs, but the mechanism of suppression of HIV-1 replication by epitope-specific CTLs still remains unknown (35, 36) . On the other hand, there are several reports indicating that epitope-specific CTLs in HLA-B + 57 LTNP have the ability to cross-recognize variant epitopes (4, 13, 46) , suggesting the control of escape 19 mutants by these CTLs. In the present study, we demonstrated the selection of escape mutations by HLA-B*5101-mediated immune pressure and showed that 2 kinds of mutations, escape mutations for slow progressors and a mutation reducing viral fitness and weakly affecting T cell recognition for LTNPs, were selected in slow-progressing and LTNP hemophiliacs.
In the present study, we showed that HLA-B*5101 + hemophiliacs exhibited significantly slow progression during [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] . Furthermore, we demonstrated that the control of HIV-1 over approximately 25 years in HLA-B*5101-positive hemophiliacs was associated with a Pol283-8-specific CD8 + T cell response. This is the first finding that a Pol-specific CTL response is more effective in the control of HIV-1 than a Gag-specific one.
Our findings provide a novel mechanism for understanding the long-term control of HIV-1 in LTNPs and slow progressors. The number of Pol283-8-specific (A), Pol743-9-specific (B), Gag327-specific (C), or
Rev71-specific (D) CD8 + T cells among PBMC from the 10 HLA-B*5101 + hemophiliacs at 1 or 2-10 different time points (see Table 1 ) was measured by using specific tetramers.
The correlation of the median of the tetramer + cell number with that of the viral load was analyzed. explains why bulky and long amino acids are not preferential. 
